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The Outcomes of Using Colistin for Treating Multidrug Resistant 
Acinetobacter Species Bloodstream Infections
Despite the identification of Acinetobacter baumannii isolates that demonstrate 
susceptibility to only colistin, this antimicrobial agent was not available in Korea until 
2006. The present study examined the outcomes of patients with multidrug resistant (MDR) 
Acinetobacter species bloodstream infection and who were treated with or without colistin 
as part of their regimen. The colistin group was given colistin as part of therapy once 
colistin became available in 2006. The non-colistin group was derived from the patients 
who were treated with other antimicrobial regimens before 2006. Mortality within 30 days 
of the onset of bacteremia occurred for 11 of 31 patients in the colistin group and for 15 of 
39 patients in the non-colistin group (35.5% vs 38.5%, respectively, P = 0.80). Renal 
dysfunction developed in 50.0% of the 20 evaluable patients in the colistin group, but in 
28.6% of the 35 evaluable patients in the non-colistin group (P = 0.11). On multivariate 
analysis, only an Acute Physiological and Chronic Health Evaluation II score ≥ 21 was 
associated with mortality at 30 days. This result suggests that administering colistin, 
although it is the sole microbiologically appropriate agent, does not influence the 30 day 
mortality of patients with a MDR Acinetobacter spp. bloodstream infection.
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INTRODUCTION
Nosocomial infections caused by Acinetobacter baumannii and 
that exhibit resistance to virtually all antimicrobial agents as-
sayed in vitro have rapidly increased in recent years (1-3). For-
tunately, these multidrug resistant strains have retained suscep-
tibility to colistin, which is a polymyxin-family antimicrobial 
agent that was used several generations ago. This finding of re-
tained colistin susceptibility has led to widespread reintroduc-
tion of the agent (4). Several studies have reported on the thera-
peutic and adverse effects associated with colistin use, and these 
studies have generally reported a favorable profile (4-6). How-
ever, there have been few well-designed studies that have eval-
uated whether the reintroduction of colistin has a meaningfully 
impact on the outcomes of patients with multidrug resistant 
(MDR) A. baumannii infections. 
  In Korea, MDR A. baumannii strains have been isolated since 
the late 1990s. Korean clinicians initially did not have access to 
colistin and they were forced to use less-than-ideal agents such 
as carbapenems, ampicillin-sulbactam, piperacillin-tazobac-
tam, cephalosporins or fluoroquinolones despite their poor per-
formance on in vitro susceptibility assay. Since parenteral colis-
tin became available in late 2006, the agent has become the first-
line treatment for MDR A. baumannii infection.
  The main objective of our study was to investigate whether 
the reintroduction of colistin improved the survival outcomes of 
patients with MDR Acinetobacter spp. bloodstream infections. 
We also compared the outcomes between in patients who were 
treated with colistin and in those who were treated without co-
listin.
 
MATERIALS AND METHODS
Study design and population 
The microbiology laboratory database was electronically que-
ried to identify all the blood cultures that were positive for Aci-
netobacter spp. from the patients admitted between June 2000 
and August 2007 at Asan Medical Center (AMC), which is a 
2,200-bed tertiary care center in Seoul, Korea. The eligible sub-
jects were all hospitalized patients with a positive blood culture 
for MDR Acinetobacter spp.; and they met the US Centers for 
Disease Control and Prevention criteria for health care-associ-Lim S-K, et al.  •  Colistin for Treating MDR Acinetobacter Bacteremia
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ated infection (7). For the patients who had more than one epi-
sode of Acinetobacter spp. bacteremia, only the first episode was 
considered. The patients with polymicrobial bloodstream infec-
tion were included. 
  The colistin group was identified as the patients who were 
treated with parenteral colistin with or without other antimicro-
bials. The patients in the non-colistin group were treated with 
either single or combination antimicrobials that the Acineto-
bacter spp. isolates were not susceptible to according to in vitro 
testing. 
  We excluded the patients younger than 12 months and the 
patients who could not receive the required treatment measures 
in addition to systemic antimicrobial therapy. Patients were ex-
cluded if they received fewer than 72 hr of antimicrobial thera-
py (8). Patients were also excluded if they were treated late, and 
this was defined as receiving the first dose of antibiotics more 
than 24 hr after the pathogen had been identified and the sus-
ceptibility testing had been completed. 
  We compared the 30-day in-hospital mortality as well as the 
clinical variables that could influence mortality among the colis-
tin treated and non-colistin-treated patients. In addition, we per-
formed a subgroup analysis of the patients who received colis-
tin as early empiric treatment until the final bacteriologic evalu-
ation was available. These patients received colistin within 48 
hr after the onset of bacteremia, but before MDR Acinetobacter 
spp. was identified. 
Colistin administration  
All the patients in the colistin group received colistimethate so-
dium methanesulfonate (SteriMax Inc., Ontario, Canada). They 
received colistin base via parenteral delivery at a dose of 2.5-5.0 
mg/kg (75,000-150,000 IU/kg) per day divided into two or three 
doses (6). Dosage adjustments were made according to the cre-
atinine clearance in the patients with renal failure based on the 
recommendations of prior reports (4).
Microbiological methods  
Standard media and techniques were used for bacterial isola-
tion and identification. Identification and antimicrobial suscep-
tibility testing for all the antimicrobial agents except colistin was 
performed using the MicroScan automated broth microdilution 
method with a MicroScan NegCombo Panel Type 32 (Dade Beh-
ring, Sacramento, CA, USA). The breakpoints were those defined 
by the Clinical and Laboratory Standards Institute (CLSI) (9). 
Intermediate sensitivity was considered resistance. Susceptibil-
ity to colistin was tested by means of the agar dilution method 
and a susceptible isolate was defined as having a minimal inhib-
itory concentration (MIC) ≤ 2.0 μg/mL according to the CLSI 
guidelines (9). Pseudomonas aeruginosa ATCC 27853 was used 
as a quality control strain (9). 
Data collection  
We collected all the available medical information including age, 
gender, the length of the intensive care unit (ICU) stay, the med-
ication history, underlying diseases and the calculated Charl-
son’s comorbidity index. Data on acute organ failure, the Acute 
Physiological and Chronic Health Evaluation II score (APACHE 
II score) and the Pitt bacteremia score on the day of bacteremia 
were also collected. Information regarding the suspected or 
proven portal of entry, the presence of polymicrobial bactere-
mia, the duration of antibiotic administration and the presence 
of other antimicrobial agents were also collected. In addition, 
laboratory data such as the complete blood counts, renal and 
liver function tests and the C-reactive protein level were col-
lected.
Operational definitions  
We defined MDR Acinetobacter spp. as strains that demonstrat-
ed in vitro resistance to all of the following antimicrobial agents; 
penicillins (ampicillin, ampicillin-sulbactam, ticarcillin-clavu-
lanate, piperacillin-tazobactam); cephalosporins (ceftriaxone, 
cefotaxime, ceftazidime, cefepime); carbapenems (imipenem, 
meropenem); aminoglycosides (tobramycin, gentamicin, amika-
cin); fluoroquinolones (ciprofloxacin, levofloxacin); and mono-
bactam (aztreonam).
  Acute organ system failure (i.e., cardiovascular, respiratory, 
renal, hematologic or central nervous system) was defined us-
ing the definitions of Zimmerman et al. (10). Acute liver failure 
was defined as the appearance of encephalopathy within 2 weeks 
of developing jaundice. 
  The diagnosis of pneumonia, intra-abdominal infection, uri-
nary tract infection, central venous catheter-related blood stream 
infection, skin and soft tissue infection and primary bacteremia 
were based on the guidelines issued by the Centers for Disease 
Control and Prevention (7).
  Normal renal function was defined as a serum creatinine lev-
el of 1.3 mg/dL or lower (8). Deterioration of renal function was 
defined as an increase of more than 50% in the baseline creati-
nine level to a value higher than 1.3 mg/dL or a decline in renal 
function that required hemodialysis (8). Irreversible renal dys-
function was defined as failure of the serum creatinine level to 
return to baseline after discontinuation of the antimicrobials. 
The baseline creatinine level was defined as the creatinine level 
on the first day of administering antimicrobial agents. 
Outcome measures  
The primary outcome measure was the overall in-hospital mor-
tality at 30 days from the day on which bacteremia was first de-
tected. Because colistin was withdrawn in the 1970s largely due 
to its association with acute renal failure, we also followed the 
effects of colistin treatment on the renal function during treat-
ment as a secondary end point. When analyzing the outcomes Lim S-K, et al.  •  Colistin for Treating MDR Acinetobacter Bacteremia
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of renal dysfunction, we excluded the patients who were already 
receiving renal replacement therapy before undergoing antibi-
otic treatment.
Statistical analysis
Categorical variables were compared by the chi-square test or 
Fisher’s exact test. For continuous variables, we used the Mann-
Whitney U test. The data is reported as the median (range) and 
the odds ratio with the 95% confidence intervals. All the tests 
were two-tailed, and statistical significance was set for P values 
< 0.05. Multivariate analysis was conducted to determine the 
adjusted odds ratios for the predictors of mortality. Variables 
with a P value < 0.05 on the univariate analysis were considered 
for inclusion in a logistic regression model. We chose a repre-
sentative variable if several variables with P values < 0.05 were 
seemed to have similar clinical relevance. Colistin treatment 
was entered into the regression model irrespective of these re-
quirements as it represented the principal variable under inves-
tigation. All the statistical analyses were performed with SPSS 
12.0 software (SPSS Inc., Chicago, IL, USA).
Ethics statement
This study was approved by the institutional review board at 
Asan Medical Center (Protocol No; AMC-IRB-2010-0510). All 
the data collected from this study was kept confidential.
 
RESULTS
Study population
Thirty-six patients who were treated with colistin for MDR Aci-
netobacter spp. bacteremia were identified. One patient was an 
infant ≤ 12 months of age, and 2 patients were excluded due to 
an insufficient duration of colistin therapy. Another two patients 
were excluded because they began colistin therapy after identi-
fying the MDR Acinetobacter spp. infection. Forty patients were 
included in the non-colistin group. One advanced malignancy 
patient was excluded because he refused drainage of an intra-
peritoneal abscess and instead requested hospice care. Finally, 
31 patients were included in the colistin group and 39 in the 
non-colistin group. 
  Colistin susceptibility tests were performed using the stored 
Table 1. Demographic and clinical characteristics of the patients in the colistin and non-colistin groups
Parameters Colistin group (n = 31) No. (%) Non-colistin group (n = 39) No. (%) P value
Age (Median years, Range)  56 (9-80) 54 (10-83) 0.89
Male gender  25 (80.6) 29 (74.4) 0.53
ICU stay at the day of suffering bacteremia 19 (61.3) 25 (64.1) 0.81
Charlson’s comorbidity index, (Median score, Range) 5 (1-9) 4 (0-9) 0.65
Underlying diseases 
   Diabetes mellitus
   Liver cirrhosis
   Solid organ malignancy
   Hematologic malignancy
   SOT recipient
   HSCT recipient
   Use of immunosuppressants* or steroids
†
 
4 (12.9)
16 (51.6)
16 (51.6)
2 (6.5)
15 (48.4)
1 (3.2)
19 (46.3)
 
7 (17.9)
13 (33.3)
17 (43.6)
5 (12.8)
11 (28.2)
3 (7.7)
22 (53.7)
 
0.74
0.12
0.50
0.45
0.08
0.62
0.68
Portal of entry
   Pneumonia
   Intra-abdominal infection
   Urinary tract infection
   Central venous catheter related BSI
   Skin and soft tissue infection
 
13 (41.9)
16 (51.7)
1 (3.2)
1 (3.2)
0 (0)
 
12 (30.8)
21 (53.8)
0 (0)
2 (5.1)
1 (2.6)
 
0.33
0.85
0.44
1.00
1.00
Primary bacteremia 0 (0) 3 (7.7) 0.25
Polymicrobial bacteremia  3 (9.7) 9 (23.1) 0.14
Laboratory findings
   ANC ≤ 500/µL 
   Platelet counts, median × 10
3/µL (range)
   Serum albumin, median g/dL (range)
 
1 (3.2)
105 (8-413)
2.7 (1.4-3.5)
 
7 (17.9)
63 (4-351)
2.6 (1.2-3.8)
 
0.07
0.23
0.81
Number of acute organ failures
‡, median (range) 2 (0-5) 1 (0-5) 0.70
Septic shock  18 (58.1) 19 (48.7) 0.44
APACHE II score, median score (range) 20 (8-45) 20 (6-52) 0.52
Pitt bacteremia score, median score (range) 3 (0-14) 3 (0-13) 0.94
Treatment
   Combination antibiotic therapy 
   Treatment duration (Median days, Range)
 
11 (35.5)
18 (4-55)
 
17 (43.6)
15 (7-40)
 
0.49
0.11
*Immunosuppressants are defined as cyclosporine, mycophenolate mofetil, tacrolimus and sirolimus and these are administered for more than 7 days; 
†Steroids mean more 
than equivalent to prednisone doses of 15mg per day for more than 7 days; 
‡Number of organ failure means the numbers of different failure statuses derived from the following 
6 categories of organ-systems: cardiovascular, respiratory, renal, hematologic, neurologic and liver. Comparison of the organ failure variables between the colistin-treated and 
non-colistin-treated groups was not significantly different (data not shown). ICU, intensive care unit; SOT, solid organ transplantation; HSCT, hematopoietic stem cell transplantation; 
BSI, blood stream infection; ANC, absolute neutrophil count; APACHE II, acute physiological and chronic health evaluation II.Lim S-K, et al.  •  Colistin for Treating MDR Acinetobacter Bacteremia
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blood isolates in the laboratory. All 31 Acinetobacter spp. iso-
lates derived from the colistin group were stored. However, for 
the case of the non-colistin group, not all the isolates had been 
stored in the laboratory, so susceptibility tests could be per-
formed to only 17 of 39 isolates. All 48 tested Acinetobacter spp. 
strains were susceptible to colistin as verified by an MIC for co-
listin ≤ 2 μg/mL, which is consistent with the CLSI guidelines (9). 
The MIC50 was 0.190 μg/mL and the MIC90 was 0.380 μg/mL in 
both groups.
Demographic and clinical characteristics  
Table 1 shows the basic demographic data and clinical features 
of our cohort, including several clinical severity indices. There 
was no significant difference between colistin and non-colistin 
groups. The two groups were similar with respect to the treat-
ment duration and the utilization of combination therapy. Twen-
ty of 31 patients (64.5%) were treated with colistin within 48 hr 
after the onset of bacteremia and they were regarded as the pa-
tients who received appropriate early empirical colistin therapy. 
Eleven patients (35.5%) in the colistin group received combina-
tion antimicrobial therapy (7 patients received carbapenems,   
4 received other combinations). Three patients (9.7%) received 
combined therapy with antimicrobial preparations that includ-
ed sulbactam such as ampicillin-sulbactam or cefoperazone-
sulbactam. 
  In the non-colistin group, commonly prescribed antimicro-
bials included carbapenems (59.0%), fluoroquinolones (51.3%) 
and piperacillin-tazobactam (28.2%) as part of either single or 
combination therapy. Antimicrobials that included sulbactam 
were administrated to 7 patients (18.0%) in the non-colistin 
group, which was not significantly different from the frequency 
of sulbactam-containing preparations in the colistin-treated 
group (P = 0.49).
Primary outcome  
The treatment outcomes are depicted in Table 2. Eleven of 31 
patients (35.5%) of the colistin group and 15 of 39 patients (38.5 
%) of the non-colistin group died within 30 days after the onset 
of bacteremia (P = 0.80) despite the fact that only the patients in 
the colistin group had received microbiologically appropriate 
treatment. All the causes of mortality were recorded as septic 
shock or multi-organ dysfunction syndrome.  
  In the colistin group, 11 patients were administered another 
antimicrobial agent simultaneously in addition to colistin and 
20 patients received colistin monotherapy. The 30 day in-hos-
pital mortality was 45.5% (5 of 11) in patients who received com-
bination therapy and 30.0% (6 of 20) in those who received co-
listin alone, and there was no significant difference (P = 0.45).
  The twenty patients who were treated empirically with colis-
tin within 48 hr from the onset of bacteremia were also studied 
as part of a subgroup analysis. All the patients in the non-colis-
tin group had been administered an antimicrobial agent at the 
time bacteremia developed. The demographic and clinical char-
acteristics between this early appropriate colistin treated sub-
group (n = 20) and the non-colistin treated group (n = 39) were 
not significantly different (data not shown). Overall 30 day mor-
tality was not significantly different. Seven of 20 patients (35.0%) 
in the subgroup of early empirical colistin therapy and 15 of 39 
patients (38.5%) in the non-colistin-treatment group died with-
in 30 days (P = 0.80).
Secondary outcome
Renal dysfunction was evaluated for the 20 patients in the colis-
tin group and for the 35 patients in the non-colistin group. When 
analyzing the outcomes of the patients with renal dysfunction, 
we excluded the patients who were already receiving renal re-
placement therapy before the administration of colistin or other 
antimicrobials. As a result, 11 of 31 patients (35.5%) were exclud-
ed in the colistin group, but only 4 of 39 patients (10.3%) were 
excluded in the non-colistin group and there was a significant 
difference (P = 0.02). The basic demographic and clinical char-
acteristics were not significantly different between the 20 pa-
tients in the colistin group and the 35 patients in the non-colis-
tin group (data not shown) except that neutropenia was more 
frequent in the non-colistin group (0% vs 20.0%, respectively, P 
= 0.04). Ten of the 20 patients (50.0%) in the colistin group and 
10 of the 31 patients (28.6%) in the non-colistin group developed 
renal insufficiency after antimicrobial treatment (Table 2), but 
there was no statistically significant difference (P = 0.11). Irre-
versible renal insufficiency developed more frequently in the 
colistin group, but this difference did not reach stostical signifi-
cance (30.0% vs 14.3%, respectively, P = 0.18). 
Mortality risk factor analysis  
Among the 70 patients enrolled, 26 died and 44 had survived 30 
days from the onset of bacteremia. The factors that might pre-
dict mortality were analyzed. Univariate analysis was performed 
initially; the significant factors from this analysis included neu-
tropenia, a platelet count ≤ 80,000/μL, pneumonia as a portal of 
entry, the intensive care unit (ICU) stay, septic shock, the pres-
ence of organ failures and a high score for either the APACHE II 
score or the Pitt bacteremia score. Multivariate analysis (Table 
3) found that an APACHE II score ≥ 21 was the only significant 
factor that could predict the overall 30 days mortality (P = 0.02). 
Table 2. Overall outcomes in the colistin and non-colistin groups
Outcomes
Colistin group  
No. (%)
Non-colistin group 
No. (%)
P 
value
Primary outcome 
   30 day mortality
 
11/31 (35.5)
 
15/39 (38.5)
 
0.80
Secondary outcome 
   Renal dysfunction
   Irreversible renal dysfunction  
 
10/20 (50.0)
  6/20 (30.0)
 
10/35 (28.6)
  5/35 (14.3)
 
0.11
0.18Lim S-K, et al.  •  Colistin for Treating MDR Acinetobacter Bacteremia
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Colistin treatment itself was not an independent risk factor of 
mortality. 
   
DISCUSSION
Interest in A. baumannii infection has been growing and maily 
because of the emergence of multidrug-resistant strains (11). 
Since many A. baumannii strains are now susceptible only to a 
single known agent, terms such as ‘colistin-only-susceptible’ or 
‘polymyxin-only-susceptible’ are now commonly used. The dif-
ficulty in treating these new drug resistant A. baumannii strains 
has led to the reintroduction of colistin without evidence of the 
efficacy beyond in vitro assays and historical experience (4, 6). 
When colistin was developed and introduced in the 1950s, the 
contemporary procedures for new drug development and clini-
cal approval were not yet in place (5). The past regulations were 
considerably looser than the current requirements, and there 
are substantial gaps in the available knowledge regarding the 
basic pharmacology of this antibiotic (6). Several studies have 
been performed in recent years in order to reevaluate the effi-
cacy and safety of colistin; the majority of these studies found 
that colistin is clinically effective with acceptable adverse effects 
(12, 13). 
  However, the available literature does not conclusively dem-
onstrate better outcomes among the patients treated with colis-
tin for MDR A. baumannii infections. The previous studies have 
lacked control group because it was ethically unacceptable to 
withhold colistin from patients with MDR A. baumannii infec-
tion; colistin was known to be the only in vitro susceptible agent 
(6). 
  Second, the previous studies usually included all the subjects 
with various health care-associated infections such as pneumo-
nia, intra-abdominal infection and surgical wound infection. A. 
baumannii is commonly colonized from endotracheal tubes, 
surgical drains and open skin wounds in hospitalized patients. 
It is quite difficult to differentiate true infection from coloniza-
tion unless A. baumannii was isolated from blood or other ster-
ile body fluids (14), and thus there is concern about overdiag-
nosing MDR A. baumannii infection. For overcoming this limi-
tation, we need abundant clinical reports of colistin based on 
only bloodstream infection (15).
  It is not an established conclusion that appropriate antimi-
crobial treatment actually improves the survival of the patients 
with an drug resistant A. baumannii bloodstream infections. 
Some recent studies have revealed that inappropriate antimi-
crobial treatment was a independent risk factor of mortality (16, 
17). However, several studies have demonstrated that appropri-
ate antimicrobial did not improve survival (15, 18, 19). Other 
studies failed to prove that appropriate treatment was an inde-
pendent risk factor for mortality (20, 21).
  Our findings indicated that there was no improvement of the 
30 day overall mortality for patients treated with colistin when it 
was used as the sole microbiologically appropriate agent. An 
association with mortality was not revealed for the subgroup of 
patients who received colistin within 48 hr after the onset of 
bacteremia. Although this result is somewhat surprising, there 
are several explanations.
  First, although A. baumannii may be quite resistant to most 
antimicrobials, the available evidence suggests it is not a highly 
virulent pathogen (22, 23). The prognosis for bacteremia caused 
by A. baumannii is controversial. On one hand, its clinical rele-
vance is under question (24). Blot et al. (25) reported that the 
calculated attributable mortality rate of A. baumannii bactere-
mia was only 7.8% and they concluded that in critically ill pa-
tients it was not associated with increased mortality. On the 
other hand, several clinical reports have offered opinions that 
are contrary to this position (13, 26). 
  Second, by studying only the cases with demonstrated bacte-
remia, we preselected the more severely ill patients than was de-
scribed in the previous reports. In our study, the median APACHE 
II score of the colistin-treated group was 20 (range: 8-45) and 
the median Pitt bacteremia score was 3 (range: 0-14). We sug-
gest that several host factors, including severe co-morbid dis-
ease, multiple organ failure and impaired immunity, may be 
more important determinants of the outcome than purely the 
susceptibility to antimicrobial agent (14, 15, 18, 25). Indeed, the 
results of our multivariate analysis showed that the APACHE II 
score was the single important factor most highly associated 
with mortality. 
  Third, it could be related to the efficacy of colistin. The effica-
cy of colistin is not yet fully accepted. Several experimental mod-
els have provided disappointing results about the efficacy of 
colistin (27, 28). It is also possible explanation that the in vivo 
effects of colistin do not correlate well with the results of in vitro 
testing (23). 
  We observed that deterioration of renal function is more com-
monly developed in patients treated with colistin (50.0% vs 28.6%, 
respectively), but this result was not statistically significant (P = 
0.11). It was possible to include only 20 patients in the colistin 
group and 35 patients in the non-colistin group in the analysis 
for the development of renal insufficiency. Patients were exclud-
Table 3. Multivariate analysis of the factors associated with the 30 day mortality after 
bacteremia
Covariates Odds ratio, death (95% CI) P value
Colistin use 1.1 (0.3-4.4) 0.89
Pneumonia 1.3 (0.3-6.0) 0.71
Neutropenia (ANC ≤ 500/µL)   4.4 (0.3-55.4) 0.25
Platelet count ≤ 80,000/µL   3.0 (0.8-12.1) 0.12
Septic shock 2.0 (0.4-9.3) 0.36
APACHE II score ≥ 21   5.6 (1.3-24.4) 0.02
ANC, absolute neutrophil count; APACHE II, acute physiological and chronic health 
evaluation II.Lim S-K, et al.  •  Colistin for Treating MDR Acinetobacter Bacteremia
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ed because receiving renal replacement therapy before under-
going antimicrobial therapy was more common in the colistin 
group than that in the non-colistin group (35.5% vs 10.3%, re-
spectively, P = 0.01). This difference could be explained by the 
prevalence of renal failure at the time of sepsis (38.7% in the co-
listin group vs 20.5% in the non-colistin group, P = 0.12) and more 
active and earlier stage application of continuous renal replace-
ment therapy at the ICU has been done in the recent years. 
  The secondary outcome analysis was complicated by the pres-
ence of several confounding factors, including hemodynamic 
instability, multi-organ system failure, injection of radiocon-
trast dye for imaging studies and the co-administration of other 
nephrotoxic therapeutic agents such as vancomycin, aminogly-
cosides and diuretics. Actually, 38 (69%) of the 55 patients in-
cluded in the analysis were treated in the ICU and 22 patients 
(40%) were in septic shock when bacteremia developed.
  The limitations of the present study include its relatively small 
size and retrospective nature, and this limits the ability to draw 
definitive conclusions about the efficacy and safety of colistin. 
Furthermore, these findings should not be broadly generalized 
beyond the conditions studied herein. For example, it remains 
to be seen whether colistin is effective for treating non-blood-
stream infections and less severely ill patients. In addition, our 
study only examined the all-cause 30 day mortality, and other 
end-points could conceivably have been affected by colistin 
treatment.
  More clinical data obtained via controlled clinical trials is 
needed to confirm our preliminary conclusions. Other reports 
from physicians with similar experiences due to the geographic 
limitations of colistin’s availability may also be extremely useful 
(29, 30). 
  In summary, our study suggests that the reintroduction of co-
listin, which is the sole microbiologically appropriate agent for 
this bacterium, does not improve the overall 30 day in-hospital 
mortality in patients who have a MDR Acinetobacter spp. blood-
stream infection. A high APACHE II score was the only signifi-
cant risk factor that could predict mortality. Our results suggest 
that the clinical severity of patients may be more important than 
concordant antimicrobial treatment for determining the out-
come of a MDR Acinetobacter spp. bloodstream infection.
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